UBS Group AG cut its position in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 72.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,072 shares of the biotechnology company’s stock after selling 15,986 shares during the period. UBS Group AG’s holdings in Five Prime Therapeutics were worth $220,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. American International Group Inc. increased its position in shares of Five Prime Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,614 shares of the biotechnology company’s stock worth $601,000 after buying an additional 1,100 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Five Prime Therapeutics by 7.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,030 shares of the biotechnology company’s stock worth $724,000 after buying an additional 1,302 shares in the last quarter. Teachers Advisors LLC increased its position in shares of Five Prime Therapeutics by 0.7% in the fourth quarter. Teachers Advisors LLC now owns 238,428 shares of the biotechnology company’s stock worth $11,948,000 after buying an additional 1,558 shares in the last quarter. Nationwide Fund Advisors increased its position in shares of Five Prime Therapeutics by 3.1% in the first quarter. Nationwide Fund Advisors now owns 59,400 shares of the biotechnology company’s stock worth $2,147,000 after buying an additional 1,771 shares in the last quarter. Finally, Creative Planning increased its position in shares of Five Prime Therapeutics by 42.6% in the first quarter. Creative Planning now owns 6,690 shares of the biotechnology company’s stock worth $242,000 after buying an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 85.10% of the company’s stock.

Five Prime Therapeutics (NASDAQ:FPRX) last released its earnings results on Thursday, May 4th. The biotechnology company reported ($1.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.25. The company had revenue of $10.13 million during the quarter, compared to analyst estimates of $6.05 million. Five Prime Therapeutics had a negative net margin of 250.98% and a negative return on equity of 21.81%. The company’s revenue for the quarter was up 55.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.49) EPS.

ILLEGAL ACTIVITY NOTICE: “UBS Group AG Sells 15,986 Shares of Five Prime Therapeutics, Inc. (FPRX)” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/07/ubs-group-ag-sells-15986-shares-of-five-prime-therapeutics-inc-fprx.html.

A number of equities analysts have commented on the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $55.00 target price on shares of Five Prime Therapeutics in a report on Thursday, June 8th. BidaskClub downgraded shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Zacks Investment Research downgraded shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 2nd. Finally, ValuEngine upgraded shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $60.83.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.